Neogenomics

NEO · NASDAQ

$16.62+$0.20 (+1.22%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $16.42

Latest news

Press releaseOct 15, 7:05 AM ETBusiness Wire
NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology
Press releaseOct 14, 7:05 AM ETBusiness Wire
NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026
NewsOct 6, 1:54 PM ETVandana Singh
What's Going On With NeoGenomics Stock Tuesday?
Press releaseOct 5, 4:05 PM ETBusiness Wire
NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan
Press releaseSep 1, 7:05 AM ETBusiness Wire
NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Press releaseAug 26, 4:17 PM ETBusiness Wire
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
NewsAug 25, 10:22 AM ETVandana Singh
Greenland Mines Outlines $2B Valuation for Sarfartoq Project
NewsJul 29, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsJul 29, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsJul 28, 4:06 PM ET
NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate
Press releaseJul 28, 4:05 PM ETBusiness Wire
NeoGenomics Reports Second Quarter 2026 Results
Press releaseJul 20, 5:23 PM ETBusiness Wire
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
Press releaseJul 9, 7:05 AM ETBusiness Wire
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Press releaseJul 7, 7:05 AM ETBusiness Wire
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Press releaseJun 25, 7:05 AM ETBusiness Wire
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
Press releaseJun 17, 6:00 AM ETBusiness Wire
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
Press releaseJun 15, 5:24 PM ETBusiness Wire
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
Press releaseMay 26, 7:05 AM ETBusiness Wire
NeoGenomics to Present New Research at ASCO Annual Meeting 2026
Press releaseMay 15, 9:05 AM ETBusiness Wire
NeoGenomics to Participate in Upcoming Investor Conferences
NewsMay 12, 7:11 AM ET
Earnings Scheduled For May 12, 2026
NewsApr 29, 8:06 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsApr 28, 4:09 PM ET
NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate
Press releaseApr 28, 4:05 PM ETBusiness Wire
NeoGenomics Reports First Quarter 2026 Results
NewsApr 28, 7:11 AM ET
Earnings Scheduled For April 28, 2026
Press releaseApr 23, 7:05 AM ETBusiness Wire
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration
Press releaseApr 13, 7:05 AM ETBusiness Wire
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026
Press releaseApr 7, 7:05 AM ETBusiness Wire
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026
NewsMar 19, 7:11 AM ET
Earnings Scheduled For March 19, 2026
Press releaseMar 16, 7:05 AM ETBusiness Wire
NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling
Press releaseFeb 25, 7:05 AM ETBusiness Wire
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
Press releaseFeb 18, 7:05 AM ETBusiness Wire
NeoGenomics to Participate in Upcoming Investor Conferences
NewsFeb 17, 7:06 AM ET
NeoGenomics Earnings Report: Q4 Overview
Press releaseFeb 17, 7:05 AM ETBusiness Wire
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
NewsFeb 16, 1:01 PM ET
Exploring NeoGenomics's Earnings Expectations
Press releaseFeb 12, 7:05 AM ETBusiness Wire
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
Press releaseJan 27, 7:05 AM ETBusiness Wire
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Press releaseJan 12, 7:05 AM ETBusiness Wire
NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue
NewsDec 30, 8:03 AM ETAvi Kapoor
Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseSep 2, 9:30 AM ETPRNewswire
Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands
NewsJul 29, 8:20 AM ETAvi Kapoor
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Press releaseFeb 18, 7:05 AM ETBusiness Wire
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
Press releaseJan 30, 9:05 AM ETGlobe Newswire
PacBio Announces Appointment of Chris Smith to Board of Directors
Press releaseJan 15, 10:10 AM ETPRNewswire
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year
Press releaseNov 5, 7:00 AM ETBusiness Wire
NeoGenomics Reports Third Quarter 2024 Results
Press releaseJul 29, 4:05 PM ETBusiness Wire
NeoGenomics Reports Second Quarter 2024 Results

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

NeoGenomics Expands Indica Labs Partnership to Scale AI-Powered Digital Pathology

NeoGenomics to Report Third Quarter 2026 Financial Results on October 28, 2026

What's Going On With NeoGenomics Stock Tuesday?

NeoGenomics Announces Executive Leadership and Board of Directors Succession Plan

NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring

Greenland Mines Outlines $2B Valuation for Sarfartoq Project

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026

NeoGenomics Appoints Carolyn Starrett to its Board of Directors

NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes

NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes

NeoGenomics to Present New Research at ASCO Annual Meeting 2026

NeoGenomics to Participate in Upcoming Investor Conferences

Earnings Scheduled For May 12, 2026

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

NeoGenomics Q1 Adj. EPS $0.01, Inline, Sales $186.672M Beat $184.509M Estimate

NeoGenomics Reports First Quarter 2026 Results

Earnings Scheduled For April 28, 2026

NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration

NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026

NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026

Earnings Scheduled For March 19, 2026

NeoGenomics' PanTracer LBx Receives Medicare Coverage, Expanding Access to Comprehensive Liquid Biopsy Profiling

NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types

NeoGenomics to Participate in Upcoming Investor Conferences

NeoGenomics Earnings Report: Q4 Overview

NeoGenomics Reports Fourth Quarter and Full Year 2025 Results

Exploring NeoGenomics's Earnings Expectations

NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection

NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

NeoGenomics Announces Preliminary Fourth Quarter and Full-Year 2025 Revenue

Ryvyl, NeoGenomics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands

Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

NeoGenomics Reports Fourth Quarter and Full Year 2024 Results

PacBio Announces Appointment of Chris Smith to Board of Directors

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

NeoGenomics Reports Third Quarter 2024 Results

NeoGenomics Reports Second Quarter 2024 Results